The grade 1 CRS resolved with symptomatic treatment alone, whereas the patient with grade 2 CRS was treated with intravenous anti-IL-6R monoclonal antibody (tocilizumab), fresh frozen plasma packs, and fluid therapy. This evidence concerns the gene IL6R and congenital rubella syndrome.